Skip to main content

Utilization Management: Coverage and Denial Processes

January 23, 2020

To: All Providers

Coverage Decisions Based on Appropriateness of Care

BlueCross BlueShield bases medical necessity decisions on the appropriateness of care and services. Coverage decisions are based on the benefits and provisions contained in patients’ contracts. We do not reward or offer incentives to practitioners, providers, or staff members for issuing denials or for encouraging inappropriate under-utilization of care.

Discussing an Adverse Determination

Practitioners who would like to discuss a denial decision based on medical necessity with our physician reviewers may do so by calling 1-800-677-3086

You may also discuss the adverse determination with our physician reviewers at the time you are notified by phone of our determination. You may request the criteria used by Utilization Management to render our decisions by calling the number above or sending a written request to:

BlueCross BlueShield of Western New York
Attn: Utilization Management
PO Box 80
Buffalo, NY 14240-0080

Recent Articles

  • Accredo is Our New Specialty Pharmacy
    Beginning April 1, 2020, Accredo will become our preferred provider of specialty medications. Accredo will replace CVS in providing these specialty medications for your BlueCross BlueShield patients. Here we outline the process for transitioning self-administered and in-office medications.
  • Ensuring Timely Secondary Insurer Payments from BlueCross BlueShield
    Electronically submitting Coordination of Benefits (COB) claims can ensure that they are processed quickly and efficiently. Here we also offer guidance on how to submit electronic Medicare crossover claims when we are the secondary insurer.
  • Annual HEDIS Campaign
    February begins our annual HEDIS Medical Record Review campaign. As we do every year, we will be requesting medical records to support the care you provide to your BlueCross BlueShield patients.
  • Update to Drug Therapy Guidelines for Stelara and Rituximab
    Updated drug therapy guidelines for Stelara and Rituximab will be posted by March 1, 2020 and effective on April 1, 2020.
  • Medical Protocol Updates Available Online
    We recently reviewed 50 medical protocols. Updates will be posted online on or before February 28, 2020 and will have an effective date of April 1, 2020, unless otherwise noted.

Working with Us

Additional Resources

We want to hear from you! Have a topic request for the next Blue Bulletin? Email us

Stay in Touch! Sign up to receive emails for provider news and information